JP2015530989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530989A5 JP2015530989A5 JP2015526762A JP2015526762A JP2015530989A5 JP 2015530989 A5 JP2015530989 A5 JP 2015530989A5 JP 2015526762 A JP2015526762 A JP 2015526762A JP 2015526762 A JP2015526762 A JP 2015526762A JP 2015530989 A5 JP2015530989 A5 JP 2015530989A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- hvr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 138
- 201000011510 cancer Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102100032702 Protein jagged-1 Human genes 0.000 claims 4
- 102100032733 Protein jagged-2 Human genes 0.000 claims 4
- 101710170213 Protein jagged-2 Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 101000994439 Danio rerio Protein jagged-1a Proteins 0.000 claims 2
- 108700003486 Jagged-1 Proteins 0.000 claims 2
- 108700037966 Protein jagged-1 Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
Images
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682640P | 2012-08-13 | 2012-08-13 | |
| US61/682,640 | 2012-08-13 | ||
| US201361784332P | 2013-03-14 | 2013-03-14 | |
| US61/784,332 | 2013-03-14 | ||
| PCT/US2013/054664 WO2014028446A1 (en) | 2012-08-13 | 2013-08-13 | Anti-jagged anitbodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018082543A Division JP6619047B2 (ja) | 2012-08-13 | 2018-04-23 | 抗ｊａｇｇｅｄ抗体および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530989A JP2015530989A (ja) | 2015-10-29 |
| JP2015530989A5 true JP2015530989A5 (cg-RX-API-DMAC7.html) | 2017-09-21 |
| JP6352264B2 JP6352264B2 (ja) | 2018-07-04 |
Family
ID=49004047
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526762A Active JP6352264B2 (ja) | 2012-08-13 | 2013-08-13 | 抗ｊａｇｇｅｄ抗体および使用方法 |
| JP2018082543A Active JP6619047B2 (ja) | 2012-08-13 | 2018-04-23 | 抗ｊａｇｇｅｄ抗体および使用方法 |
| JP2019204815A Active JP7366700B2 (ja) | 2012-08-13 | 2019-11-12 | 抗ｊａｇｇｅｄ抗体および使用方法 |
| JP2021131076A Withdrawn JP2021191275A (ja) | 2012-08-13 | 2021-08-11 | 抗ｊａｇｇｅｄ抗体および使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018082543A Active JP6619047B2 (ja) | 2012-08-13 | 2018-04-23 | 抗ｊａｇｇｅｄ抗体および使用方法 |
| JP2019204815A Active JP7366700B2 (ja) | 2012-08-13 | 2019-11-12 | 抗ｊａｇｇｅｄ抗体および使用方法 |
| JP2021131076A Withdrawn JP2021191275A (ja) | 2012-08-13 | 2021-08-11 | 抗ｊａｇｇｅｄ抗体および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10113002B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2882776B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6352264B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20200143502A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104520328B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015003032B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2880271C (cg-RX-API-DMAC7.html) |
| MX (2) | MX381841B (cg-RX-API-DMAC7.html) |
| RU (2) | RU2018130986A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014028446A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014008212A2 (pt) | 2011-10-05 | 2017-06-13 | Genentech Inc | método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar |
| KR20150037857A (ko) | 2012-06-22 | 2015-04-08 | 싸이톰스 테라퓨틱스, 인크. | 항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법 |
| US10113002B2 (en) | 2012-08-13 | 2018-10-30 | Genentech, Inc. | Anti-jagged antibodies and methods of use |
| US10350216B2 (en) * | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| HK1211963A1 (en) | 2013-03-15 | 2016-06-03 | 豪夫迈．罗氏有限公司 | Compositions and methods for diagnosis and treatment of hepatic cancers |
| CA2936565C (en) | 2014-02-12 | 2020-08-11 | Genentech, Inc. | Anti-jagged1 antibodies and methods of use |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| JOP20190259A1 (ar) * | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004924A (en) | 1991-12-11 | 1999-12-21 | Imperial Cancer Research Technology, Ltd. | Protein sequences of serrate gene products |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20030170636A1 (en) | 2002-03-05 | 2003-09-11 | Isis Pharmaceuticals Inc. | Antisense modulation of jagged 2 expression |
| US20030185829A1 (en) | 2002-03-12 | 2003-10-02 | Erich Koller | Jagged 2 inhibitors for inducing apoptosis |
| US20040101847A1 (en) | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Notch2 expression |
| WO2004019921A2 (en) | 2002-08-29 | 2004-03-11 | University Of Southampton | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases |
| NZ540555A (en) | 2002-11-15 | 2008-04-30 | Genmab As | Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders |
| US7285269B2 (en) | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| AU2004294563B2 (en) * | 2003-11-26 | 2009-03-26 | Health Research, Inc. | Use of notch pathway interfering agents for treatment of plasma cell disorders |
| ZA200701234B (en) | 2004-07-22 | 2008-12-31 | Genentech Inc | HER2 antibody composition |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| AT502055B1 (de) | 2005-06-21 | 2007-11-15 | Univ Wien Med | Anti tumor medikament |
| WO2008057144A2 (en) | 2006-05-15 | 2008-05-15 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1 |
| NZ577274A (en) | 2006-12-18 | 2012-10-26 | Genentech Inc | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| CA2676008A1 (en) * | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| EP2125896A2 (en) | 2007-02-09 | 2009-12-02 | Genetech, Inc. | Anti-robo4 antibodies and uses therefor |
| US8802103B2 (en) | 2007-05-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| US7988967B2 (en) | 2007-08-10 | 2011-08-02 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
| JP2009078998A (ja) | 2007-09-26 | 2009-04-16 | Univ Of Tokushima | Ｊａｇｇｅｄ２を用いる制癌剤 |
| US8557965B2 (en) * | 2008-04-07 | 2013-10-15 | Ablynx N.V. | Single variable domains against notch pathway members |
| PT2307051E (pt) | 2008-07-08 | 2015-05-21 | Oncomed Pharm Inc | Antagonistas e agentes de ligação a notch e métodos de utilização dos mesmos |
| CN102264763B (zh) | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| WO2010039832A1 (en) | 2008-10-01 | 2010-04-08 | Genentech, Inc. | Anti-notch2 antibodies and methods of use |
| BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
| US8945569B2 (en) * | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
| BR112014008212A2 (pt) | 2011-10-05 | 2017-06-13 | Genentech Inc | método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar |
| KR20150037857A (ko) | 2012-06-22 | 2015-04-08 | 싸이톰스 테라퓨틱스, 인크. | 항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법 |
| US10113002B2 (en) | 2012-08-13 | 2018-10-30 | Genentech, Inc. | Anti-jagged antibodies and methods of use |
| HK1211963A1 (en) * | 2013-03-15 | 2016-06-03 | 豪夫迈．罗氏有限公司 | Compositions and methods for diagnosis and treatment of hepatic cancers |
| CA2936565C (en) | 2014-02-12 | 2020-08-11 | Genentech, Inc. | Anti-jagged1 antibodies and methods of use |
| BR112017000130A2 (pt) * | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
-
2013
- 2013-08-13 US US14/421,103 patent/US10113002B2/en active Active
- 2013-08-13 BR BR112015003032-7A patent/BR112015003032B1/pt not_active IP Right Cessation
- 2013-08-13 RU RU2018130986A patent/RU2018130986A/ru unknown
- 2013-08-13 MX MX2018004827A patent/MX381841B/es unknown
- 2013-08-13 RU RU2015108797A patent/RU2666990C2/ru active
- 2013-08-13 KR KR1020207035928A patent/KR20200143502A/ko not_active Ceased
- 2013-08-13 EP EP13751040.0A patent/EP2882776B1/en active Active
- 2013-08-13 CA CA2880271A patent/CA2880271C/en active Active
- 2013-08-13 WO PCT/US2013/054664 patent/WO2014028446A1/en not_active Ceased
- 2013-08-13 KR KR1020157006164A patent/KR102193080B1/ko not_active Expired - Fee Related
- 2013-08-13 JP JP2015526762A patent/JP6352264B2/ja active Active
- 2013-08-13 MX MX2015001942A patent/MX357675B/es active IP Right Grant
- 2013-08-13 CN CN201380041607.8A patent/CN104520328B/zh active Active
-
2018
- 2018-04-23 JP JP2018082543A patent/JP6619047B2/ja active Active
- 2018-09-20 US US16/136,478 patent/US10689455B2/en active Active
-
2019
- 2019-11-12 JP JP2019204815A patent/JP7366700B2/ja active Active
-
2020
- 2020-05-12 US US16/872,631 patent/US11702479B2/en active Active
-
2021
- 2021-08-11 JP JP2021131076A patent/JP2021191275A/ja not_active Withdrawn
-
2023
- 2023-05-22 US US18/321,249 patent/US20240034805A1/en not_active Abandoned